Modern radionuclide methods in diagnosing orbital masses

Cover Page

Cite item

Full Text

Abstract

Anatomic and topographic features of orbit structure and similar clinical symptoms in many diseases of different etiologies explain the complicated early diagnosis of orbital diseases. Therefore, the diagnostic algorithm for orbital masses is mainly based on instrumental diagnostic methods, especially radiology. Over the past 20-30 years, radiologic diagnosis of orbital tumors took a step forward thanks to the introducing such methods as computer tomography, magnetic resonance imaging and ultrasound into clinical practice. However, these methods of investigation, despite their great diagnostic possibilities, not always allow to obtain objective information on the tumor biology, tumor malignancy grade and characteristics of their metabolism. A significant step forward in this direction was the development and introduction of modern nuclear medicine techniques such as single photon emission computed tomography and positron emission (two-photon) tomography into clinical practice. These methods allow to visualize the functional processes in normal conditions and to perform a kind of non-invasive biopsy in case of neoplastic disorders. The use of nuclear medicine in oncology is based on hyperfixation of some radiopharmaceuticals in malignant tumors that provides important data for diagnosis and differential diagnosis based on the study of physiological and biological tumor features. The review highlights brief historical facts, as well as the results of using the most informative and safe radiopharmaceuticals. Literature analysis concludes that radionuclide tests at some point might be a method of choice for differential diagnosis of orbital masses.

About the authors

L R Altynbaeva

Medical and sanitary unit of JSC «Tatneft» and the city of Almetyevsk, Almetyevsk, Russia

Author for correspondence.
Email: lianaaltynbaeva@rambler.ru

A F Gabdrakhmanova

Bashkir State Medical University, Ufa, Russia

Email: lianaaltynbaeva@rambler.ru

References

  1. Бровкина А.Ф. Офтальмоонкология. Руководство для врачей. - М.: Медицина, 2002. - 424 с.
  2. Бровкина А.Ф. Актуальные вопросы офтальмоонкологии // Вестн. офтальмол. - 1997. - Т. 113, №1. - С. 5-7.
  3. Габдрахманова А.Ф., Алтынбаева Л.Р. Возможности сцинтиграфии в дифференциальной диагностике гемангиом орбиты // Офтальмохирургия. - 2006. - №4. - С. 46-48.
  4. Габдрахманова А.Ф., Алтынбаева Л.Р. Радионуклидное исследование с применением однофотонной эмиссионной компьютерной томографии в дифференциальной диагностике злокачественных и доброкачественных новообразований орбиты // Вестн. офтальмол. - 2008. - Т. 124, №4. - С. 39-41.
  5. Дубинская Л.Р., Вальский В.В. Количественная характеристика радионуклидной сцинтиграфии при некоторых заболеваниях орбиты / Опухоли и опухолеподобные заболевания органа зрения. - М., 1990. - С. 71-73.
  6. Лишманов Ю.Б., Чернова В.И. Радионуклидная диагностика для практических врачей. - Томск: STT, 2004. - 387 с.
  7. Медведский В.Е., Гренков Г.И., Щербинин Ю.И., Павлова Л.А. Радионуклидная диагностика в онкологии // Новости лучев. диагн. - 1999. - №1. - С. 32-34.
  8. Burggasser G., Hurtl I., Hauff W. et all. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves disease // J. Nucl. Med. - 2003. - Vol. 44, N 10. - P. 1547-1555.
  9. Burroni L., Borsari G., Pichierri P. et al. Preoperative diagnosis of orbital cavernous hemangioma: a 99mTc - RBC SPECT study // Clin. Nucl. Med. - 2012. - Vol. 37. - P. 11. http://dx.doi.org/10.1097/RLU.0b013e318252d2ed
  10. Burroni L., Polito E., Tasciotti A. et al. The Tc99m-RBC SPECT in the diagnosis of orbital cavernous hemangioma // J. Nucl. Med. - 2000. - Vol. 44. - P. 70.
  11. Chan-Kai B.T., Yen M.T. Combined positron emission tomography/computed tomography imaging of orbital lymphoma // Am. J. Ophthalmol. - 2005. - Vol. 140, N 3. - P. 531-533. http://dx.doi.org/10.1016/j.ajo.2005.02.044
  12. Colao A., Lastoria S., Ferone D. et al. Orbital scintigraphy with [111In-Diethylenetriamine Pentaacetic Acid-D-Phe1]-Octreotide predicts the clinical response to corticosteroid therapy in patients with Graves’ ophthalmopathy // J. Clin. Endocrinol. Metab. - 1998. - Vol. 83, N 11. - P. 3790-3794.
  13. Iannetti G., Valentini C., Rinna C. et al. Ethmoido-orbital tumors: our experience // J. Craniofac. Surg. - 2005. - Vol. 16, N 6. - P. 1085-1091. http://dx.doi.org/10.1097/01.SCS.0000164332.81428.BA
  14. Isidori A.M., Kaltsas G., Frajese V. et al. Ocular metastases secondary to carcinoid tumors: the utility of imaging with [123I]Meta-Iodobenzylguanidine and [111In]DTPA Pentetreotide // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87. - P. 1627-1633. http://dx.doi.org/10.1210/jcem.87.4.8407
  15. Galushka L., Leovey A., Szucs-Farcas Z. et al. Imaging of disease activity in Graves orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores // Nucl. Med. Common. - 2005. - Vol. 26. - P. 5.
  16. Gayed I., Eskandari M.F., McLaughlin P. et al. Value of positron emission tomography in staging ocular adnexal limphomas and evaluating their response to therapy // Ophthalmic. Surg. Lasers Imaging. - 2007. - Vol. 38, N 4. - P. 319-325.
  17. Ka-Hoi H., Margaret L., Pfeifer E., Bita E. Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors // Saudi. J. Ophthalmol. - 2012. - Vol. 26, N 4. - P. 365-371. http://dx.doi.org/10.1016/j.sjopt.2012.08.008
  18. Kim H.Y., Lee S.Y., Kang S.J. et al. Solitary fibrous tumor of the orbit: a poorly-recognized orbital lesion // Acta. Ophthalmol. Scand. - 1999. - Vol. 77, N 6. - P. 704-708. http://dx.doi.org/10.1034/j.1600-0420.1999.770621.x
  19. Klingensten A., Haug A.R., Nentwich M.M. et al. Whole-body F-18-fluoro-2-dezoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma // Melanoma Res. - 2010. - Vol. 20, N 6. - P. 511-516. http://dx.doi.org/10.1097/CMR.0b013e3283403d6c
  20. Lemke A.J., Kazi I., Felix R. Magnetic resonance imaging of orbital tumors // Eur. Radiol. - 2006. - Vol. 16, N 10. - P. 2207-2219. http://dx.doi.org/10.1007/s00330-006-0227-0
  21. Polito E., Burroni L., Loffredo A., Vattimo A.G. Technetium Tc99m-labeled red blood cells in the preoperative diagnosis of cavernous hemangioma and other vascular tumors // Arch. Ophthalmol. - 2005. - Vol. 123, N 23. - P. 1678-1683. http://dx.doi.org/10.1001/archopht.123.12.1678
  22. Razi M., Mohamed A.S., Lejla S., Medhat M.O. Ophthalmologic abnormalities on FDG-PET/CT: a pictorial essay // Cancer Imaging. - 2013. - Vol. 13, N 1. - P. 100-112. http://dx.doi.org/10.1102/1470-7330.2013.0010
  23. Rebelo Pinto E.S., Lopes F.P., de Souza S.A. et al. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in Graves ophthalmopathy patients with different clinical activity score // Horm. Metab. Res. - 2013. - Vol. 45, N 10. - P. 765-768. http://dx.doi.org/10.1055/s-0033-1349891
  24. Roe R.H., Finger P.T., Kurli M. et al. Whole-body positron emission tomography. Computed tomography imaging and staging of orbital lymphoma // Ophthalmology. - 2006. - Vol. 113, N 10. - P. 1854-1858. http://dx.doi.org/10.1016/j.ophtha.2006.04.029
  25. Romero-Aroca P., Montero-Jaime M., Intriago B. et al. 18FDG-PET/CT assessing the absence of cell viability and excluding metastatic disease in a case of necrotic choroidal melanoma // Eur. J. Ophthalmol. - 2012. - Vol. 22, N 2. - P. 288-292. http://dx.doi.org/10.5301/ejo.5000016
  26. Sayt E., Durak I., Capakaya G. et al. The role of -99m RBC scintigraphy in the differential diagnosis of orbital cavernous hemangioma // Ann. Nucl. Med. - 2001. - Vol. 15. - P. 149-151. http://dx.doi.org/10.1007/BF02988606
  27. Shulman J.P., Latkany P., Chin K.J., Finger P.T. Whole-body 18FDG PET-CT. Imaging of systemic sarcoidosis: ophthalmic oncology and uveitis // Ocul. Immunol. Inflam. - 2009. - Vol. 17, N 2. - P. 95-100. http://dx.doi.org/10.1080/09273940802596567
  28. Sun H., Jiang X.F., Wang S. et al. (99m)Tc HYNIC-TOC scintigraphy in evaluation of active Graves’ ophthalmopathy (GO) // Endocrine. - 2007. - Vol. 31, N 3. - P. 305-310. http://dx.doi.org/10.1007/s12020-007-0039-2
  29. Szabados L., Nagy E.V., Ujhelyi B. et al. The impact of 99mTc-DTPA orbital SPECT in patient selection for external radiation therapy in Graves’ ophthalmopathy // Nucl. Med. Commun. - 2013. - Vol. 34, N 2. - P. 108-112. http://dx.doi.org/10.1097/MNM.0b013e32835c19f0

© 2015 Altynbaeva L.R., Gabdrakhmanova A.F.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies